CERVOMED INC (CRVO) Surges 11.6%: Is This an Indication of Further Gains?
- CERVOMED INC (CRVO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- 07/28/2025
|
CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
- Based on the primary endpoint of Clinical Dementia Rating Sum of Boxes (CDR-SB), patients treated with neflamapimod showed 54% risk reduction in clinically significant worsening compared to control at Week 32 of treatment (p=0.0037). This risk reduction improved to 64% (p=0.0001) among patients who have minimal evidence of AD co-pathology (ptau181 < 2.2 pg/mL at screening)
- 07/28/2025
|
CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025
- BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver Developing Topics (late-breaking) virtual and in-person poster presentations at Alzheimer's Association® International Congress (AAIC) 2025, being held on July 27 – 31, 2025 in Toronto, Canada. The Company will be presenting the results, including new results, from the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB).
- 07/08/2025
|
CervoMed Inc. (CRVO) Reports Q1 Loss, Tops Revenue Estimates
- CervoMed Inc. (CRVO) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.41 per share a year ago.
- 05/12/2025
|
CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
- Reported positive 16-week results from the extension phase of the Phase 2b RewinD-LB trial, demonstrating proof-of-concept for neflamapimod as a potential treatment for dementia with Lewy bodies (DLB)
- 05/12/2025
|
Biotech Stocks Q1 2025 Recap: Winners And Underperformers
- Investing in biotech can be highly rewarding but is fraught with risks; understanding past catalysts can help investors make informed decisions and minimize downside risk. CervoMed Inc. surged over 300% in Q1 2025 due to positive Phase 2b trial results for its lead drug candidate, neflamapimod despite earlier setbacks. Chimerix Inc. gained over 144% after announcing an acquisition by Jazz Pharmaceuticals and positive FDA feedback on its lead drug candidate, dordaviprone.
- 03/31/2025
|
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)
- BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced it will deliver an oral presentation at the 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™), being held on April 1-5, 2025 in in Vienna, Austria. The Company will be presenting detailed analyses from the Extension Phase of the RewinD-LB Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB).
- 03/25/2025
|
CervoMed: Extension Study Data In Dementia With Lewy Bodies Is Potentially Exciting, With Caveats
- CervoMed's stock surged more than 400% after interim data showed significant improvement with a new batch of neflamapimod in treating Dementia with Lewy Bodies. The recent interim readout deserves excitement, but I do express several concerns related to, among others, potential learning and placebo effects, subjective CDR-SB results, and lack of biomarker data. CervoMed is well-funded into 2026, but may need additional funds for further trials to bring neflamapimod to market for DLB.
- 03/22/2025
|
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
- A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p
- 03/10/2025
|
CervoMed to Present at the 8th International Lewy Body Dementia Conference
- BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the Phase 2b RewinD-LB study will be presented at the 8th International Lewy Body Dementia Conference (ILBDC), being held in Amsterdam, on January 31, 2025. The initial topline results for the Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) were previously disclosed on December 10, 2024 and are available here.
- 01/29/2025
|
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- BOSTON, Dec. 12, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO) (the “Company”), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has granted equity awards as a material inducement to the employment of two new employees.
- 12/12/2024
|
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets
- On Tuesday, CervoMed Inc. CRVO stock is trading lower after the company revealed topline data from the RewinD-LB Phase 2b clinical trial evaluating neflamapimod for dementia with Lewy bodies (DLB).
- 12/10/2024
|
CervoMed's stock craters 77% after failed trial of treatment for rare brain disease
- CervoMed Inc.'s stock cratered early Tuesday after the biotech company said a midstage trial of a treatment for patients with dementia with Lewy bodies, or DLB, failed to meet its main goals.
- 12/10/2024
|
CervoMed's dementia drug fails to meet mid-stage trial goals
- U.S. drug developer CervoMed said on Tuesday its experimental drug for a common degenerative brain disease did not meet the main or secondary goals in a mid-stage clinical trial.
- 12/10/2024
|
CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
- —Neflamapimod did not demonstrate statistically significant effects versus placebo on primary and secondary endpoints at 16 weeks—
- 12/10/2024
|
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
- Designation underscores significant unmet need in frontotemporal dementia and the potential role of neflamapimod in multiple neurologic disorders
- 11/27/2024
|
CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
- - Reported last patient, last visit in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with early-stage dementia with Lewy bodies (DLB) in October 2024; topline data expected in December 2024 –
- 11/12/2024
|
CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
- The Prix Galien USA Best Startup category recognizes outstanding innovation by therapeutics-focused life science companies that have not yet received their first product approval
- 11/08/2024
|
CervoMed to Participate in Upcoming Investor Conferences
- BOSTON, Nov. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company's Management will participate in the following investor conferences during the month of November:
- 11/07/2024
|
CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
- Data from the AscenD-LB Phase 2a trial in DLB confirm recent scientific literature indicating that plasma glial fibrillary acid protein (GFAP) is a robust measure of neurodegenerative disease activity in DLB
- 11/04/2024
|
CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
- Topline data from the RewinD-LB Phase 2b study on track for December 2024 Detailed safety and efficacy data from RewinD-LB Phase 2b study to be featured in an oral presentation at the ILBDC conference in January 2025 BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that it will deliver an oral presentation providing detailed safety and efficacy results from its completed RewinD-LB Phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB) at the eighth International Lewy Body Dementia Conference (ILBDC) taking place on January 29-31, 2025 in Amsterdam, the Netherlands. “As we await topline results from the RewinD-LB Phase 2b trial in DLB, we are extremely encouraged by the scientific community's interest in the data and pleased to have an opportunity to present them at the leading scientific conference dedicated to Lewy Body Dementia,” said John Alam, MD, Chief Executive Officer of CervoMed.
- 10/29/2024
|
CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
- Dr. John Alam to Participate in Panel Titled “Opportunities and Challenges When Small Names Go After Blockbuster Indications” Dr. John Alam to Participate in Panel Titled “Opportunities and Challenges When Small Names Go After Blockbuster Indications”
- 10/02/2024
|
CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?
- CERVOMED INC (CRVO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
- 09/20/2024
|
CervoMed to Participate in Upcoming Investor Conferences
- BOSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that the Company's management will participate in the following investor conferences during the month of September:
- 08/27/2024
|
CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
- BOSTON, Aug. 22, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced its recent feature in Fortune magazine.
- 08/22/2024
|
CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference
- BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company's Management will participate in a fireside chat at the Canaccord Genuity 44th Annual Growth Conference, to be held in Boston, MA, and participate in one-on-one investor meetings.
- 07/30/2024
|
CervoMed to Participate in the Emerging Growth Conference
- BOSTON, July 17, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company's Management will present virtually at the Emerging Growth Conference.
- 07/17/2024
|
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
- BOSTON, July 11, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, July 23, 2024 at 10:00 AM ET.
- 07/11/2024
|
Have 20 Bucks? 7 Low-Priced Stocks That Could Double by 2025
- Low-priced stocks to buy with the potential to double within the next year or so have inherent appeal for investors. Individual shares are affordable making it relatively easy to establish a stake.
- 06/28/2024
|
CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
- - Topline data expected in December 2024 - - Phase 2b design optimized for success; clear path to market in this high value indication expected with positive result - BOSTON, June 11, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that it has completed enrollment in RewinD-LB, a Phase 2b trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB). “Drug development for the major dementias over the past decade has progressively focused on earlier stages of disease.
- 06/11/2024
|
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
- Shares of Virios Therapeutics, Inc. VIRI fell sharply during Monday's session after the company priced a $1.7 million public offering of 8.5 million shares of common stock at $0.20 per share. Virios Therapeutics shares dipped 47.6% to $0.1850 on Monday. Here are some other stocks moving in today’s mid-day session. MultiMetaVerse Holdings Limited MMV shares jumped 224% to $2.01. MultiMetaVerse Holdings signed a non-binding term sheet to acquire 100% of Bowong Technology (Shenzhen) Co., Ltd. and its subsidiaries. GT Biopharma, Inc. GTBP rose 146% to $7.64. GT Biopharma, last week, posted a narrower-than-expected quarterly loss. Tantech Holdings Ltd TANH jumped 89.8% to $1.2501. Faraday Future Intelligent Electric Inc. FFIE shares gained 62.1% to $1.6701. Faraday Future Intelligent Electric is scheduled to report its fourth quarter and full year 2023 results after the closing bell on Tuesday, May 28. CN Energy Group. Inc. CNEY surged 58% to $1.0501. Scorpius Holdings, Inc. SCPX gained 57.8% to $0.1635. Scorpius, last week, announced closing of public offering. NKGen Biotech, Inc. NKGN rose 46% to $1.6250 after the company’s SNK01 NK Cell Therapy was cleared to begin a Phase 2 trial in Alzheimer’s disease. Bruush Oral Care Inc. BRSH jumped 41% to $0.1658. Rekor Systems, Inc. REKR gained 36% to $1.80 after the company announced a partnership with MS2. MIRA Pharmaceuticals, Inc. MIRA gained 34.3% to $0.8866 after the company said it has advanced new preclinical studies using Ketamir-2 towards clinical development. Scilex Holding Company SCLX gained 34% to $1.21. Hims & Hers Health, Inc. HIMS rose 30.5% to $19.01 after the company announced the addition of GLP-1 injections to its weight loss portfolio. BYND Cannasoft Enterprises Inc. BCAN surged 29.5% to $1.4250. Cheetah Mobile Inc. CMCM gained 24.3% to $5.70. Concord Medical Services Holdings Limited CCM jumped 23% to $0.6188. Wix.com Ltd. WIX rose 21.6% to $164.94 as the company posted upbeat results for its first quarter and raised its 2024 forecast on Monday. Sintx Technologies, Inc. SINT shares rose 21.1% to $0.1029 after dipping over 39% on Friday. Sutro Biopharma, Inc. STRO climbed 17.6% to $4.7150. PTC Therapeutics, Inc. PTCT jumped 17.2% to $38.78 after the company announced the European Commission has returned the Translarna opinion to the CHMP for re-evaluation. Cue Health Inc. HLTH gained 17.1% to $0.1128 after dipping around 18% on Friday. Cue Health, last week, announced that it voluntarily and temporarily paused sales and distribution of its EUA COVID-19 Test Cartridge. NextDecade Corporation NEXT climbed 16% to $8.10 after ADNOC announced it secured an equity position and LNG offtake agreement in NextDecade’s Rio Grande LNG project. NuScale Power Corporation SMR rose 15.5% to $7.29. VinFast Auto Ltd. VFS gained 15% to $5.61. Crown ElectroKinetics Corp. CRKN shares rose 14.8% to $0.1964 after falling around 29% on Friday. Tellurian Inc. TELL gained 14% to $0.5870. Shineco, Inc. SISI shares climbed 10.2% to $1.09 after jumping 19% on Friday. Shineco recently announced that its subsidiaries Fuzhou Medashan Biotechnology and Kaifeng Yixi Biotechnology invented a new natural active water-soluble product. Independent Bank Group, Inc. IBTX gained 8.5% to $47.69 after SouthState announced it will acquire the company. Doximity, Inc. DOCS surged 5.1% to $29.46. Akoustis Technologies, Inc. AKTS fell 53.8% to $0.1647 after Qorvo won a jury verdict against the company in a trade secret misappropriation and patent infringement case. Cheetah Net Supply Chain Service Inc. CTNT declined 48% to $5.61. FLJ Group Limited FLJ shares fell 44.5% to $0.86 after surging 224% on Friday. Jaguar Health, Inc JAGX fell 39.8% to $0.1557 after the company announced a 1-for-60 reverse stock split. Fangdd Network Group Ltd. DUO declined 38% to $1.04. Jeffs’ Brands Ltd JFBR shares declined 35.8% to $0.4189 after jumping 109% on Friday. DermTech, Inc. DMTK fell 33.8% to $0.3302. CervoMed Inc. CRVO declined 25.3% to $17.99. CervoMed named William Elder as Chief Financial Officer, effective June 1. Barnes & Noble Education, Inc. BNED dipped 22.6% to $0.3482. Akanda Corp. AKAN shares fell 22.3% to $0.1339 following a 30% surge on Friday. iPower Inc. IPW shares fell 20.8% to $2.29 after jumping 98% on Friday. iPower, last week, reported better-than-expected third-quarter financial results. Nature’s Miracle Holding Inc. NMHI declined 19.9% to $0.5396. Nature’s Miracle mutually agreed to terminate plan to merge with Agrify Corp. Li Auto Inc. LI fell 12.6% to $21.74 after the company reported worse-than-expected first-quarter results and issued second-quarter guidance. GameStop Corp. GME declined 10% to $19.99. Oklo Inc. OKLO fell 8.6% to $8.23. IGM Biosciences, Inc. IGMS declined 8.2% to $8.46. Cemtrex, Inc. CETX shares fell 7.6% to $0.45 after climbing 49% on Friday. Cemtrex, last week, posted a wider quarterly loss. The Beauty Health Company SKIN declined 5.8% to $2.58. Inovio Pharmaceuticals, Inc. INO fell 5.6% to $11.33. ATRenew Inc. RERE shares fell 4.3% to $2.71 after reporting weak quarterly earnings. Now Read This: How To Earn $500 A Month From Lowe’s Stock Ahead Of Q1 Earnings Report © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/20/2024
|
CervoMed to Appoint William Elder as Chief Financial Officer
- BOSTON, May 20, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced the appointment of William (Bill) Elder as Chief Financial Officer, effective June 1, 2024. Mr. Elder will continue to serve as General Counsel and Corporate Secretary. He will succeed William Tanner who has served as Chief Financial Officer to CervoMed and its predecessor, EIP Pharma, since September 2022. Mr. Tanner will continue as a consultant to CervoMed following the transition.
- 05/20/2024
|
CervoMed Reports First Quarter 2024 Financial Results and Provides Corporate Updates
- - CervoMed on track to complete enrollment in 2Q 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies (DLB); topline data expected in 4Q 2024-
- 05/15/2024
|
CervoMed: H2 2024 Data For DLB Program A Major Inflection Point
- Results from the phase 2b RewinD-LB study, using neflamapimod for the treatment of patients with Dementia With Lewy bodies, are expected in the 2nd half of 2024. The global Lewy body Dementia treatment market is projected to reach $8.45 billion by 2033. If targeting of p38 alpha protein to inhibit synaptic dysfunction works for DLB, then potential to apply the same mechanism of action towards Alzheimer's Disease, Frontotemporal dementia, and other neurological disorders.
- 04/02/2024
|
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
- - Announced private placement of up to $149.4 million led by RA Capital Management with participation from Armistice Capital, Special Situations Funds and Soleus Capital; pro forma cash and cash equivalents from upfront proceeds expected to provide runway through the end of 2025
- 04/01/2024
|
CervoMed to Participate in Upcoming Investor Conferences
- BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that Company's Management will participate in the following three investor conferences during the month of April:
- 03/28/2024
|
CervoMed Announces Up to $149.4 Million Private Placement Financing Joined by Leading Healthcare Investors
- Funding from new investors, including RA Capital Management, Armistice Capital, Special Situations Funds and Soleus Capital
- 03/28/2024
|
CervoMed Announces Presentation of Biomarker Data from the AscenD-LB Phase 2a Trial and Preclinical Data Supporting Potential of Neflamapimod in Tau-Mediated Disease at AD/PD ™ 2024
- - Neflamapimod led to significant reduction compared to placebo in plasma levels of glial fibrillary acidic protein (GFAP)
- 03/05/2024
|
CervoMed to Participate in the BIO CEO and Investor Conference
- BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company's Management will present at the BIO CEO and Investor Conference on February 26, 2024, being held in New York, NY and participate in one-on-one investor meetings.
- 02/21/2024
|
CervoMed Publishes Positive Results from AscenD-LB Phase 2a Trial in Peer-Reviewed Journal that Supports the Therapeutic Potential of Neflamapimod in Dementia with Lewy Bodies
- -Integrated summary of all previously published Phase 2a clinical results, together with the first peer reviewed publication of EEG and MRI results, substantially derisk the ongoing RewinD-LB Phase 2b trial of neflamapimod in dementia with Lewy bodies -
- 02/12/2024
|
CervoMed Announces Appointment of Industry Leader Joshua Boger, Ph.D., as Chair of the Board
- Dr. Boger is the founder, and retired CEO and Board Chair, of Vertex Pharmaceuticals CervoMed on track to complete enrollment in 1H 2024 in its RewinD-LB Phase 2b clinical trial evaluating neflamapimod in patients with dementia with Lewy bodies; topline data expected in 2H 2024 BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company developing treatments for degenerative diseases of the brain, today announced the appointment of Joshua Boger, Ph.D., to its Board of Directors (Board) and as Chair of the Board.
- 02/07/2024
|
CervoMed to Participate in the Emerging Growth Conference 67
- BOSTON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company's Management will provide a corporate update at the Emerging Growth Conference 67, to be held virtually from February 7-8, 2024.
- 02/05/2024
|
CervoMed to Participate in the Emerging Growth Conference 66
- BOSTON, Jan. 05, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced that Company's Management will provide a corporate update at the Emerging Growth Conference 66, to be held virtually from January 10-11, 2024.
- 01/05/2024
|
CervoMed Reports Third Quarter 2023 Financial Results and Business Highlights
- Dosed first patient in Phase 2b RewinD-LB study evaluating neflamapimod in patients with dementia with Lewy bodies (DLB) Multiple peer-reviewed journal publications and a conference presentation inform on the potential of neflamapimod in DLB and probability of success in optimized RewinD-LB study Completed reverse merger; company now publicly traded on Nasdaq ("CRVO") CervoMed has cash runway through the end of 2024, by which time the topline primary efficacy results from the Phase 2b RewinD-LB study are expected to be available BOSTON , Nov. 13, 2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced financial results for the third quarter ended September 30, 2023, and provided recent business highlights. "This has been an active and exciting quarter as we completed our merger and launch of CervoMed, while also enrolling the first patient in our RewinD-LB Phase 2b study of neflamapimod for dementia with Lewy bodies (DLB)," said John Alam, MD, Chief Executive Officer of CervoMed.
- 11/13/2023
|
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Learnings from Phase 2a Which Optimized the Design of the Phase 2b Clinical Study of Neflamapimod in Dementia with Lewy Bodies
- With incorporation of key learnings, Phase 2b has >95% (approaching 100%) statistical power to meet its primary endpoint: change in Clinical Dementia Rating Sum-of-Boxes (CDR-SB) vs. placebo New data included in the presentation show that in patients without Alzheimer's-related co-pathology, neflamapimod treatment demonstrates significant reduction vs.
- 10/25/2023
|
CervoMed Announces Publications in Major Peer-Reviewed Journals That Inform on Potential of Neflamapimod as a Disease-Modifying Therapy for the Major Dementias
- Final publication in Neurology® of Phase 2a Results Stratified by Plasma Phosphorylated Tau Status at Baseline Strengthens the Case for Progressing Neflamapimod as a Disease-Modifying Treatment for Dementia with Lewy Bodies Research Highlight Article in Molecular Neurodegeneration Comments That Through Acting on Cholinergic Degeneration Neflamapimod Has Potential to have Disease-modifying Effects in Both Dementia with Lewy Bodies and Alzheimer's Disease BOSTON , Oct. 24, 2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for degenerative diseases of the brain, today announced the publication of the following two articles that support advancing neflamapimod as a disease-modifying treatment for Dementia with Lewy Bodies (DLB) and Alzheimer's Disease (AD): Alam JJ, Maruff P, Doctrow S, Chu H-M, Conway J, Gomperts SN, Teunissen C. Association of plasma phosphorylated tau with the response to neflamapimod treatment in patients with dementia with Lewy bodies.
- 10/24/2023
|
CervoMed Announces Oral Presentation at CTAD 2023 Highlighting Phase 2b Neflamapimod Program for the Treatment of Patients with Dementia with Lewy Bodies
- Oral neflamapimod has the potential to reverse synaptic dysfunction, improve neuron health and slow or prevent disease progression, which would make it the first disease-modifying treatment in DLB Phase 2b RewinD-LB study underway; completion of enrollment planned in 1H 2024, and topline primary efficacy results in expected in 2H 2024 BOSTON , Oct. 18, 2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced it will present deeper insights highlighting the neflamapimod clinical development program, including findings in phase2a that led to the final Phase 2b study design for the treatment of patients with dementia with Lewy bodies (DLB), in an oral presentation at the 16th Clinical Trials in Alzheimer's Disease (CTAD) conference, being held October 24-27, 2023, in Boston, Massachusetts. "We are pleased to have the opportunity to comprehensively present the findings in phase 2a and discuss the analyses that went into optimizing the Phase 2b study design for the treatment of patients with DLB at the upcoming CTAD conference," said John Alam, MD, Chief Executive Officer of CervoMed.
- 10/18/2023
|
CervoMed to Present at the 2023 Roth Healthcare Opportunities Conference
- BOSTON , Oct. 5, 2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced it will participate in the 2023 Roth Healthcare Opportunities Conference on Thursday, October 12, 2023 in New York. Members of the Company's senior management team will be presenting and hosting 1x1 meetings at the conference.
- 10/05/2023
|
CervoMed to Present at H.C. Wainwright 25th Annual Global Investment Conference
- BOSTON , Sept. 5, 2023 /PRNewswire/ -- CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced that the Company's senior management team will present at the H.C.
- 09/05/2023
|
CervoMed Announces Completion of Merger with EIP Pharma
- Shares of CervoMed to commence trading on Nasdaq under new ticker symbol "CRVO" on August 17, 2023 CervoMed will be focused on advancing oral stress kinase inhibitor neflamapimod for the treatment of dementia with Lewy bodies and other degenerative diseases of the brain CervoMed has a cash runway through Phase 2b clinical data which is expected during 2H 2024 BOSTON , Aug. 16, 2023 /PRNewswire/ -- CervoMed Inc. (formerly known as Diffusion Pharmaceuticals Inc.) (NASDAQ: CRVO), now a clinical-stage company focused on developing treatments for degenerative diseases of the brain, today announced the closing of its previously announced merger with EIP Pharma Inc. The combined company will operate under the name CervoMed Inc., and its shares will commence trading on a 1-for-1.5 reverse split adjusted basis on August 17, 2023, on the Nasdaq Capital Market under the ticker symbol "CRVO". CervoMed's focus will be on advancing its lead drug candidate neflamapimod, an oral stress kinase inhibitor, which is currently being developed for the treatment of dementia with Lewy bodies (DLB) and other degenerative diseases of the brain.
- 08/16/2023
|
Diffusion Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
- CHARLOTTESVILLE, Va., May 17, 2022 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., the Company's President and Chief Executive Officer, will be presenting at the H.C. Wainwright Global Investment Conference being held at the Fontainebleau Miami Beach Hotel from May 23-26, 2022.
- 05/17/2022
|
5 Stocks Halted In Tuesday's Session
- A circuit breaker is an automatic, temporary trading halt on specific securities when the underlying stock is experiencing times of high volatility. It is a measure to help restore and bring order to the markets.
- 04/19/2022
|
Diffusion Pharmaceuticals (DFFN) Stock: 1-For-50 Reverse Stock Split Announced
- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) announced it will effect a 1-for-50 reverse stock split of its common stock. These are the details.
- 04/18/2022
|
Diffusion Pharmaceuticals' 50-For-1 Stock Split Will Go Into Effect Tomorrow
- Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) will effect a 1-for-50 reverse stock split of its common stock. The reverse stock split is expected to become effective and commence trading on a post-split basis at the market's opening on April 19.
- 04/18/2022
|
Why Diffusion Pharmaceuticals Shares Are Falling
- Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) shares are trading lower by 20.83% at $0.21 after the company announced a 1-for-50 reverse stock split. Diffusion Pharmaceuticals says the reverse stock split is expected to become effective at 5:59 p.m.
- 04/18/2022
|
Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P.
- CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc . (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, announced today that the Company will present at H.C. Wainwright BioConnect and participate in Biotech Showcase and BIO Partnering at JPM. All three events are scheduled alongside the J.P. Morgan 40th Annual Healthcare Conference 2022.
- 12/20/2021
|
Diffusion Pharmaceuticals (DFFN) Stock: Why The Price Increased Today
- The stock price of Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) increased by over 5% during intraday trading today. This is why it happened.
- 12/01/2021
|
Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility
- Check these three biotech penny stocks out for your list this month The post Hot Biotech Penny Stocks to Watch As New Variant Creates Volatility appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 11/29/2021
|
7 Biotech Penny Stocks With Huge Catalysts Coming in 2022
- With a new year fast approaching, these biotech penny stocks may benefit from the shifting winds in the broader healthcare market. The post 7 Biotech Penny Stocks With Huge Catalysts Coming in 2022 appeared first on InvestorPlace.
- 10/14/2021
|
Diffusion Pharmaceuticals Issues Letter to Shareholders
- CHARLOTTESVILLE, Va., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced that Robert Cobuzzi, Jr., Ph.D., Chief Executive Officer, has issued a Letter to Shareholders. The letter provides an update on recent events and outlook for the remainder of 2021 and early 2022.
- 09/09/2021
|
Diffusion Pharmaceuticals to Present at the 23rd Annual H.C. Wainwright Global Investment Conference
- Conference to Take Place Virtually, September 13-15, 2021 Conference to Take Place Virtually, September 13-15, 2021
- 09/08/2021
|
DFFN Stock: Over 7% Increase Pre-Market Explanation
- The stock price of Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) increased by over 7% pre-market. This is why it happened.
- 08/30/2021
|
Diffusion Pharmaceuticals Announces Clearance of IND Application for TSC by FDA's Pulmonology, Allergy, and Critical Care Division
- Phase 2 DLCO Trial in Interstitial Lung Disease Expected to Begin in Q4 Under New IND
- 08/30/2021
|
Diffusion Pharmaceuticals Reports Q2 Financial Results and Provides Business Update
- CHARLOTTESVILLE, Va., Aug. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for the second quarter of 2021 and provided a business update.
- 08/11/2021
|
Making a List of Penny Stocks to Buy? Here's 7 to Watch in Summer 2021
- Does your list of penny stocks to watch include these 7 hot small-caps? The post Making a List of Penny Stocks to Buy?
- 07/07/2021
|
7 Trending Penny Stocks That You Need to Know About in July 2021
- Are these trending penny stocks worth adding to your watchlist? The post 7 Trending Penny Stocks That You Need to Know About in July 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/30/2021
|
Diffusion Pharma's TSC Shows Encouraging Effects On Oxygenation
- Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) has announced topline results from the Phase 1 trial of its lead product candidate, trans sodium crocetinate (TSC). In the trial, transcutaneous oxygen monitoring (TCOM) was used to measure the direct pharmacodynamic effects of TSC on peripheral tissue oxygenation in healthy volunteers.
- 06/30/2021
|
Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial
- Trial Dosed Healthy Volunteers with Trans Sodium Crocetinate Trial Dosed Healthy Volunteers with Trans Sodium Crocetinate
- 06/30/2021
|
Diffusion Pharmaceuticals to Webcast Live at Life Sciences Investor Forum
- Presentation Scheduled for June 24, 2021 at 11:30 a.m., EDT Presentation Scheduled for June 24, 2021 at 11:30 a.m., EDT
- 06/21/2021
|
Diffusion Pharmaceuticals Reminds Stockholders to Vote Shares In Advance of Annual Meeting
- Annual Meeting Scheduled for June 25, 2021, at 1 p.m. EDT Annual Meeting Scheduled for June 25, 2021, at 1 p.m. EDT
- 06/18/2021
|
Best Penny Stocks Today? 4 Small-Cap Stocks To Watch Under $1 In June
- Hot Penny Stocks Under $1 To Watch This Month The post Best Penny Stocks Today? 4 Small-Cap Stocks To Watch Under $1 In June appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 06/09/2021
|
Diffusion Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update
- CHARLOTTESVILLE, Va., May 10, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for the first quarter of 2021 and provided a business update.
- 05/10/2021
|
Top Biotech Penny Stocks on Reddit? Check These 3 Out
- Biotech penny stocks are back in focus; should these 3 be on your watchlist? The post Top Biotech Penny Stocks on Reddit?
- 04/30/2021
|
Diffusion Pharmaceuticals Completes Enrollment and Dosing in TCOM Study
- CHARLOTTESVILLE, Va., March 25, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced it has completed enrollment and dosing of all participants in the Company's Phase 1 trial of its novel, oxygen enhancing therapeutic, trans sodium crocetinate (“TSC”), utilizing a transcutaneous oxygen monitoring (TCOM) device to evaluate the pharmacodynamic effects of TSC on peripheral tissue oxygenation.
- 03/25/2021
|
Diffusion Pharmaceuticals Reports 2020 Financial Results and Provides Business Update
- CHARLOTTESVILLE, Va., March 17, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies that enhance the body's ability to deliver oxygen to areas where it is needed most, today announced financial results for 2020 and provided a business update.
- 03/17/2021
|
Diffusion Pharmaceuticals Announces Closing of $30 Million Bought Deal Offering of Common Stock
- CHARLOTTESVILLE, Va., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative biopharmaceutical company developing novel therapies to deliver oxygen to areas of the body where it is needed most, announced today the closing of its previously announced underwritten public offering of 29,268,294 shares of its common stock at a price to the public of $1.025 per share, less underwriting discounts and commissions. As previously announced, the Company has granted the underwriter a 30-day option to purchase up to 4,390,244 additional shares of its common stock at the public offering price, less underwriting discounts and commissions.
- 02/17/2021
|
DFFN Stock Price Increases Over 20% Pre-Market: Why It Happened
- The stock price of Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) is trading at over 20% pre-market. This is why it happened.
- 02/16/2021
|
Diffusion Pharmaceuticals Completes Phase 1b Study of TSC in Hospitalized COVID-19 Patients
- No Dose Limiting Toxicities or Serious Adverse Events Observed in Dosing Regimen Previously Untested in Clinical Trial Setting No Dose Limiting Toxicities or Serious Adverse Events Observed in Dosing Regimen Previously Untested in Clinical Trial Setting
- 02/16/2021
|
Diffusion Pharmaceuticals Increases Previously Announced Bought Deal Offering of Common Stock to $30 Million
- CHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company developing novel therapies to enhance the diffusion of oxygen to tissues with low oxygen levels, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 29,268,294 shares of common stock of the Company at a price to the public of $1.025 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 17, 2021, subject to satisfaction of customary closing conditions.
- 02/11/2021
|
Diffusion Pharmaceuticals Announces $10 Million Bought Deal Offering of Common Stock
- CHARLOTTESVILLE, Va., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), an innovative clinical stage biopharmaceutical company developing novel therapies to enhance the diffusion of oxygen to tissues with low oxygen levels, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co. under which the underwriter has agreed to purchase on a firm commitment basis 9,756,098 shares of common stock of the Company at a price to the public of $1.025 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 17, 2021, subject to satisfaction of customary closing conditions.
- 02/11/2021
|
Diffusion Pharmaceuticals to Participate in H.C. Wainwright BioConnect 2021 Conference
- CHARLOTTESVILLE, Va., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), today announced that the Company is participating in the H.C. Wainwright BioConnect 2021 Conference being held virtually January 11-14, 2021. Conference specifics are as follows:
- 01/11/2021
|
Diffusion Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Business Updates
- Initiated and Advanced C linical Trial Evaluating Lead Product Candidate in COVID-19 Patients
- 11/12/2020
|
Акции «Яндекса» на рекордном уровне: аналитики одобряют сделку с «Тинькофф Банк»
- Инвесторы вкладываются в акции «Яндекса» после сделки, которая сделает технологический гигант ведущей российской финтех-компанией.
- 09/24/2020
|
Ligand Acquisitions, And Other News: The Good, Bad And Ugly Of Biopharma
- Ligand inks deal to acquire Taurus and xCella Biosciences. Zogenix reports positive data from pivotal Phase 3 clinical trial.
- 09/14/2020
|
Insider Buys TriState Capital's Shares
- TriState Capital Holdings Inc (NASDAQ:TSC) was trading 1.3% higher from the previous closing price. A Form 4 filing filed with the SEC on Wednesday, August 19 showed that CEO TSC...
- 08/19/2020
|
Relief Therapeutics Discovers A Promising COVID-19 Killer (OTCMKTS:RLFTF)
- Relief Therapeutics is in advanced clinical trials with their drug RLF-100 which aims to halt COVID-19 and reverse its devastating effects; Just-released Compassionate Use results showed stunning results: ventilator-dependent Covid-19 patients with deadly co-morbidities coming off the ventilator and returning home in only five days after treatment with RLF-100; Relief Therapeutic's RLF-100 is both easy to manufacture at scale and inexpensive, meaning that success in clinical trials could translate to rapid worldwide production and availability; If in-progress clinical trials reflect the Compassionate Use results, RLF-100 will likely garner immediate approval and shares could go much higher.
- 08/11/2020
|
CEL-SCI Corporation Reports Third Quarter Fiscal 2020 Financial Results
- CEL-SCI Corporation reports third quarter fiscal 2020 financial results.
- 08/11/2020
|
Diffusion Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Business Update
- Continues global clinical development of TSC for the treatment of COVID-19CHARLOTTESVILLE, Va., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to deliver oxygen to the areas where it is needed most, today reported financial results for the three and six months ended June 30, 2020 and provided a business update. Highlights from the second quarter of 2020 and recent weeks include: * Initiation of an international clinical development program in hospitalized patients with COVID-19. Low oxygen levels occur as a consequence of damage to the lungs from COVID-19, often resulting in mechanical ventilation and, if that is ineffective, multiple organ failure – the leading cause of death from COVID-19. Diffusion believes that the oxygen-enhancing mechanism of action of TSC could benefit such patients. * The TSC/Covid-19 clinical development program will begin with an open-label lead-in trial which, if successful, will be followed by one or more randomized double-blinded clinical trials. The lead-in trial will test TSC in 24 hospitalized COVID-19 patients at the Romanian National Institute of Infectious Diseases (NIID). Diffusion expects to begin dosing in this study in the third quarter, with data read-out in the fourth quarter of 2020. In addition to safety, the lead-in trial will collect data on possible increased oxygenation, thereby helping the Company determine TSC dosing for follow-on studies. * Following the recent successful completion of the 19-patient open-label, dose-escalation lead-in safety portion of the trial, the Company has continued pursuit of partnership efforts for its Phase 3 INTACT (INvestigating Tsc Against Cancerous Tumors) program with TSC plus standard of care (SOC) for patients newly diagnosed with inoperable glioblastoma multiforme (GBM). * The Company’s Phase 2 160-patient on-ambulance clinical trial testing TSC for the treatment of acute stroke continues, but on a limited basis because of the on-going pandemic. This program, featuring the PHAST-TSC (Pre-Hospital Administration of Stroke Therapy-TSC) trial, will ultimately involve a total of 23 hospitals across urban, suburban and rural areas in Los Angeles County and Central Virginia when conditions permit more robust operations. * On May 29, 2020 the Company”) announced that it received written notice from the Nasdaq Listing Qualifications Staff of the NASDAQ Stock Market LLC (“Nasdaq”) stating that the Company regained compliance with the applicable Nasdaq minimum bid price continued listing standard and the matter was now closed. * During the quarter, the Company sold common stock raising $10.3 million and also raised $7.6 million from the exercise of outstanding warrants, for net proceeds of $17.9 million during the reporting period.“This is an exciting time for Diffusion as we prepare for first enrollment in our global clinical trial program using TSC for the treatment of hospitalized COVID-19 patients,” said David Kalergis, chairman and chief executive officer of Diffusion. “Given the severity of the worldwide pandemic, regulatory authorities in the U.S. and Europe have put in place measures to expedite the testing of therapeutics and have been generous in their guidance in light of emerging knowledge. Protocol changes based on this guidance have been incorporated into the development program so that data from any patient, wherever located, can be included to help support planned future regulatory filings in both the U.S. and Europe. “We also raised funds during the quarter, which will largely be used to advance our TSC clinical development plan, with an emphasis on the COVID-19 program,” Mr. Kalergis continued. “At quarter-close we had more than $25 million in cash, the largest cash balance on hand since becoming a public company. In addition, to better help our investors, potential partners and the public stay informed, we are currently revamping our website to reflect the impact of our COVID-19 program on TSC’s development, with the revised website launch targeted for later this quarter.” Second Quarter Financial Results Research and development expenses were $2.2 million for the second quarter of 2020, compared with $1.5 million for second quarter of 2019. The increase was attributable to a $0.6 million increase in costs associated with follow on work for our 19 patient run-in Phase 3 trial for GBM, a $0.3 million increase in expense related to our open-label Phase 1b lead-in trial for TSC in COVID-19 patients, and a $0.3 million increase in associated manufacturing costs as we ramp up the trial. These increases were offset in part by a $0.5 million decrease in costs associated with the delay in our Phase 2 stroke trial due to the COVID-19 pandemicGeneral and administrative expenses were $1.5 million for the second quarter of 2020, compared with $1.1 million for the second quarter of 2019. The increase was mainly due to higher professional fees, salaries and wages.Diffusion had cash and cash equivalents of $25.6 million as of June 30, 2020, compared with $14.2 million as of December 31, 2019. During the second quarter the Company completed an offering of 11.4 million shares of common stock for net proceeds of $10.3 million. In addition, the Company received proceeds of $7.6 million from the exercise of 13.0 million warrants and the exchange and exercise of a further 5.0 million warrants. Diffusion believes its cash and cash equivalents as of June 30, 2020 are sufficient to fund operating expenses and capital expenditures, including clinical trials, into the fourth quarter of 2021.About Diffusion Pharmaceuticals Inc.Diffusion Pharmaceuticals Inc. is an innovative biotechnology company developing new treatments that improve the body’s ability to deliver oxygen to the areas where it is needed most, offering new hope for the treatment of life-threatening medical conditions. Diffusion’s lead drug trans sodium crocetinate (TSC) was originally developed in conjunction with the U.S. Office of Naval Research, which was seeking a way to treat multiple organ failure and its resulting mortality caused by low oxygen levels from blood loss on the battlefield. Evolutions in research have led to Diffusion’s focus today on addressing some of medicine’s most intractable and difficult-to-treat diseases, including multiple organ failure from respiratory distress, stroke and glioblastoma multiforme (GBM) brain cancer. In each of these diseases, lack of available oxygen presents a significant obstacle for medical providers and is the target for TSC’s novel mechanism. The Company is currently partnering with both U.S. and European-based institutions in an expedited research program to develop TSC as a treatment for the low oxygen levels and associated multiple organ failure in COVID-19 patients.In 2019, the Company reported favorable safety data in a 19-patient dose-escalation run-in to its Phase 3 INTACT program using TSC to target inoperable GBM. That trial is currently paused while the Company searches for a partner and prioritizes its resources to address COVID-19. Diffusion’s in-ambulance PHAST-TSC trial for acute stroke began enrolling patients last year. Given the responsibilities of the Company’s participating emergency medical services providers, enrollment in this trial, while not officially paused, is expected to be minimal until the COVID-19 pandemic abates.Preclinical data support the potential for TSC as a treatment for other conditions where low oxygen availability plays an important role, such as myocardial infarction, peripheral artery disease, and neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease. In addition to the development of TSC, RES-529, the Company’s PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes, is in preclinical testing for GBM.Diffusion is headquartered in Charlottesville, Virginia – a hub of advancement in the life science and biopharmaceutical industries – and is led by CEO David Kalergis, a 30-year industry veteran and company co-founder.Forward-Looking StatementsTo the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company's plans, objectives, expectations and intentions with respect to future operations and products, the potential of the company's technology and product candidates, and other statements that are not historical in nature, particularly those that utilize terminology such as "would," "will," "plans," "possibility," "potential," "future," "expects," "anticipates," "believes," "intends," "continue," "expects," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the Diffusion’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include: the uncertainty as to whether the FDA will approve the IND submission for commencement of a trial in the U.S.; or that the FDA will not require significant changes that might take significant time to implement, if at all, or that any such required changes will be financially feasible; there can be no assurance as to when the program in the U.S.
- 08/10/2020
|
GW Pharmaceuticals PLC (GWPH) Q2 2020 Earnings Call Transcript | The Motley Fool
- GWPH earnings call for the period ending June 30, 2020.
- 08/07/2020
|
GW Pharma shares slide 12% after company swings to loss during pandemic
- Shares of GW Pharmaceuticals PLC undefined slumped 12% Friday, after the company swung to a loss in the second quarter, hurt by the effect of the coronavirus...
- 08/07/2020
|
GW Pharmaceuticals plc. (GWPH) CEO Justin Gover on Q2 2020 Results - Earnings Call Transcript
- GW Pharmaceuticals plc. (NASDAQ:GWPH) Q2 2020 Results Earnings Conference Call August 06, 2020, 04:30 PM ET Company Participants Stephen Schultz - VP, IR Justin Gover - CEO & Executive Director Darren Cline - U.S.
- 08/07/2020
|
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2020 Financial Results
- Marinus Pharmaceuticals provides an update on its clinical development activities and reports financial results for the second quarter of 2020.
- 08/06/2020
|
FDA Approves Epidiolex to Treat Tuberous Sclerosis Complex | Ganjapreneur
- The Food and Drug Administration has expanded the label for the cannabis-derived pharmaceutical Epidiolex to treat seizures associated with tuberous… Read More
- 08/03/2020
|
Virgin Galactic Unveils Mach 3 Aircraft Design for High Speed Travel, and Signs Memorandum of Understanding with Rolls-Royce
- Virgin Galactic Holdings, Inc. (NYSE: SPCE) (“Virgin Galactic”), a vertically integrated aerospace and space travel company, which includes its manufa
- 08/03/2020
|
KNUT faults TSC for excluding its members from salary increment
- NAIROBI, Kenya Jul 29 – The Kenya National Union of Teachers (KNUT) on Wednesday accused the Teachers Service Commission (TSC) of discrimination for excluding teachers on its roll from a pay rise. KNUT said for the last one year, the TSC has been preparing two parallel payrolls, one for teachers under KNUT and another one for […]
- 07/29/2020
|
Diffusion Pharmaceuticals Receives FDA Guidance for International Phase 1b/2b COVID-19 Clinical Program with TSC
- Guidance being incorporated into global study protocol Enrollment of first patient now expected in AugustCHARLOTTESVILLE, Va., July 27, 2020 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “Company”), a biotechnology company developing novel therapeutics for the treatment of unmet medical needs, today announced receipt of guidance from the U.S. Food and Drug Administration (FDA) on the Company’s recently-filed Investigational New Drug (IND) application for trans sodium crocetinate (TSC) in COVID-19 patients. This guidance suggests certain study design changes with regard to endpoints and statistical considerations that Diffusion believes will enhance the prospect of regulatory approvals upon program completion, should the clinical results be favorable.Because these changes will be harmonized throughout the overall TSC global development program, they are being submitted for clearance by the Romanian National Agency for Medicines and Medical Devices (NAMMD). NAMMD has regulatory oversight over the Company’s first planned clinical trial, an open-label Phase 1b lead-in trial in 24 hospitalized COVID-19 patients at the Romanian National Institute of Infectious Diseases (NIID).The Company previously announced expectations that the first patient would be enrolled in the Phase 1b study by the end of July. Considering the FDA’s suggested protocol modifications and an additional NAMMD review cycle, the Company now expects the first patient will be enrolled by the end of August, with first data available early in the fourth quarter of 2020.“Getting the clinical trial protocol right is imperative as it will support regulatory reviews and determinations,” said David Kalergis, chief executive officer of Diffusion. “We are grateful for the FDA’s guidance. Incorporating their views into the Romanian arm of the program will delay the program start by just a few weeks, yet should have no material impact on overall program timelines.”About TSC and COVID-19Patients with COVID-19 respiratory tract infections often present with significantly impaired oxygen levels. Diffusion and its affiliated researchers believe the oxygen-enhancing mechanism of action of TSC could benefit such patients. Preclinical data indicate TSC increases oxygen availability and provides a functional benefit in animal models of acute lung injury and hemorrhagic shock. Clinical data from more than 150 patients receiving TSC for other indications demonstrate that the drug has an acceptable safety profile in both healthy and critically ill patients.About Diffusion Pharmaceuticals Inc.Diffusion Pharmaceuticals Inc. is an innovative biotechnology company developing new treatments that improve the body’s ability to deliver oxygen to the areas where it is needed most, offering new hope for the treatment of life-threatening medical conditions. Diffusion’s lead drug trans sodium crocetinate (TSC) was originally developed in conjunction with the U.S. Office of Naval Research, which was seeking a way to treat multiple organ failure and its resulting mortality caused by low oxygen levels from blood loss on the battlefield. Evolutions in research have led to Diffusion’s focus today on addressing some of medicine’s most intractable and difficult-to-treat diseases, including multiple organ failure from respiratory distress, stroke and glioblastoma multiforme (GBM) brain cancer. In each of these diseases, lack of available oxygen presents a significant obstacle for medical providers and is the target for TSC’s novel mechanism. The Company is currently partnering with both U.S. and European-based institutions in an expedited research program to develop TSC as a treatment for the low oxygen levels and associated multiple organ failure in COVID-19 patients.In 2019, the Company reported favorable safety data in a 19-patient dose-escalation run-in to its Phase 3 INTACT program using TSC to target inoperable GBM. That trial is currently paused while the Company prioritizes its resources to address COVID-19. Diffusion’s in-ambulance PHAST-TSC trial for acute stroke began enrolling patients last year. Given the responsibilities of the Company’s participating emergency medical services providers, enrollment in this trial, while not officially paused, is expected to be minimal until the COVID-19 pandemic abates.Preclinical data support the potential for TSC as a treatment for other conditions where low oxygen availability plays an important role, such as myocardial infarction, peripheral artery disease, and neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease. In addition to the development of TSC, RES-529, the Company’s PI3K/AKT/mTOR pathway inhibitor that dissociates the mTORC1 and mTORC2 complexes, is in preclinical testing for GBM.Diffusion is headquartered in Charlottesville, Virginia – a hub of advancement in the life science and biopharmaceutical industries – and is led by CEO David Kalergis, a 30-year industry veteran and company co-founder.Forward-Looking StatementsTo the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the company's plans, objectives, expectations and intentions with respect to future operations and products, the potential of the company's technology and product candidates, and other statements that are not historical in nature, particularly those that utilize terminology such as "would," "will," "plans," "possibility," "potential," "future," "expects," "anticipates," "believes," "intends," "continue," "expects," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause the Diffusion’s actual results to be materially different than those expressed in or implied by such forward-looking statements. Particular uncertainties and risks include: the uncertainty as to whether the FDA will approve the IND submission for commencement of a trial in the U.S.; or that the FDA will not require significant changes that might take significant time to implement, if at all, or that any such required changes will be financially feasible; there can be no assurance as to when the program in the U.S. might be able to commence, if at all; the uncertainty that as of yet the FDA has not approved a trial evaluating TSC for the treatment of ARDS, or if approved, such a trial possibly entailing significant additional time, effort and expense, particularly in light of the difficulty of doing business during the COVID-19 pandemic; the uncertainty as to whether the protocol for the Romanian trial will be ultimately acceptable to the Romanian healthcare regulatory authorities and local ethics committees or that such regulators will not require significant changes that might take significant time to implement, if at all, or that any such required changes will be financially feasible; moreover, if this or a revised protocol is acceptable to the Romanian regulators, there can be no assurance as to when they might provide such guidance or when the program might be able to commence, if at all; the uncertainty that as of yet the Romanian regulators have not approved a trial evaluating TSC for the treatment of ARDS, or if approved, such a trial possibly entailing significant additional time, effort and expense, particularly in light of the difficulty of doing business during the COVID-19 pandemic; whether Diffusion can enroll and complete the trials and provide data on the timelines indicated; whether Diffusion can efficiently transition from the Phase 1b to Phase 2b portion of the Romanian trials and to the 2b U.S. trial; whether the data from the Romanian trials can be combined with data generated in any U.S. trials; whether Diffusion has sufficient funding to complete the trials described; Diffusion’s ability to maintain its Nasdaq listing, market conditions, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; general business and economic conditions; the company's need for and ability to obtain additional financing or partnering arrangements; and the various risk factors (many of which are beyond Diffusion’s control) as described under the heading “Risk Factors” in Diffusion’s filings with the United States Securities and Exchange Commission. All forward-looking statements in this news release speak only as of the date of this news release and are based on management's current beliefs and expectations. Diffusion undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.Contacts: David Kalergis, CEO Diffusion Pharmaceuticals Inc. (434) 825-1834 dkalergis@diffusionpharma.com or LHA Investor Relations Kim Sutton Golodetz (212) 838-3777 kgolodetz@lhai.com
- 07/27/2020
|
Analysis of Glioblastoma Multiforme (GBM) in 7MM, Forecast to 2030 - United States, Germany, France, Italy, Spain, United Kingdom and Japan - ResearchAndMarkets.com
|
Indigenous Australians paying more for groceries in a regional town
- The Torres Shire Council (TSC) has sensationally accused regional supermarket Community Enterprise Queensland (CEQ) of selling overpriced goods to indigenous Australians.
- 07/15/2020
|
High-Grade Glioma Market Insights, Epidemiology and Forecast to 2030 - ResearchAndMarkets.com
|
Tata Consultancy Service (TCS) Launches Crypto Trading Solution For Indian Banks
- Tata Consultancy Services Limited (TSC) has launched a crypto trading solution for Indian banks and financial institutions.
- 07/08/2020
|
Diffusion Pharmaceuticals Files IND for International Phase 1b/2b COVID-19 Clinical Program With TSC
- This IND, which incorporates pre-IND regulatory guidance from the FDA, describes an international clinical development program in the U.S. and EU, newly titled as Phase 1b/2b, testing the Company’s lead drug TSC in a total of approximately 424 COVID-19 patients with symptoms of impaired respiratory function and low oxygen levels. Low oxygen levels are a frequent result of damage to the lungs, often leading to organ failure – the leading cause of death in COVID-19 patients.
- 07/07/2020
|
3 Coronavirus Penny Stocks With Triple-Digit Upside Potential
- Out on the Street, it’s full speed ahead. Despite the chaotic events of 2020, the S&P; 500, which is coming off of its best quarter in more than 20 years, is down by only 2% year-to-date. Somewhat remarkably, the market has continued to charge forward as the number of new COVID-19 cases surges. As COVID-19 could be with us in waves for some time, there’s plenty of uncertainty going forward into the second half of the year. Consequently, spotting compelling plays can feel like a fool’s errand, especially given the hefty toll the virus has already taken on companies spanning multiple sectors.Having said that, the Street’s pros argue that the pandemic has actually positioned some names as beneficiaries. Looking specifically at the biotech sector, massive amounts of capital have been pumped into a handful of names racing to develop solutions to combat the virus.Bearing this in mind, we used TipRanks’ database to get more information on three biotech penny stocks, trading for less than $5 per share, that are poised for COVID-related gains. While these tickers are risky in nature, the investing platform revealed that each has earned a Moderate or Strong Buy consensus rating from the analyst community and boasts substantial upside potential. CTI BioPharma Corporation (CTIC)Focused on the development of innovative therapies, CTI BioPharma wants to address the unmet medical needs of patients. Given the potential of its COVID-19 treatment and its $1.18 share price, it’s no wonder this healthcare name is on Wall Street’s radar.CTIC scored major investor attention after it initiated the Phase 3 PRE-VENT study of its pacritinib asset in COVID patients, with the study evaluating whether the therapy can reduce the occurrence of acute respiratory distress syndrome (ARDS). It should be noted that the study will include cancer patients, and initial data is expected by YE:20.Writing for Needham, five-star analyst Chad Messer points out that ARDS, which is caused by an overreaction of the immune system, is the leading cause of mortality in COVID-19 patients. What makes CTIC’s therapy a stand-out, in Messer’s opinion, is that unlike ruxolitinib, it doesn’t target JAK1. This is important as JAK1 inhibition has been associated with immune-suppression towards infections.“Pacritinib also inhibits CSF-1R which is associated with macrophage activation. Additionally, pacritinib is less thrombocyotpenic than other JAK inhibitors. These features differentiate pacritinib and may make it a potential best in class JAK inhibitor for treatment of severe COVID infection,” Messer commented. To this end, Messer continues to give CTIC his stamp of approval. Along with a Buy rating, the top analyst keeps the price target at $3.50. Should the target be met, a twelve-month gain of 195% could be in the cards. (To watch Messer’s track record, click here)Other analysts also take a bullish approach. CTIC’s Strong Buy consensus rating breaks down into 3 Buys and zero Holds or Sells. Additionally, the $3.50 average price target matches Messer’s. (See CTIC stock analysis on TipRanks)PhaseBio Pharmaceuticals (PHAS)When it comes to PhaseBio, its focus lands squarely on the lack of new treatment options for serious cardiovascular diseases. Even though the pandemic has created challenges for the company, several members of the Street believe it can overcome these obstacles, with its $4.39 price tag reflecting an attractive entry point.Five-star analyst Andrew Fein, of H.C. Wainwright, reminds investors that its lead candidate, PB2452, which was designed to reverse ticagrelor antiplatelet effects in major uncontrolled bleeding and urgent emergency surgery events, has entered its pivotal Phase 3 trial. While this is exciting, the analyst doesn’t dispute that COVID-19 has spurred headwinds.Expounding on this, Fein stated, “Specifically, ERs have focused their attention on treating COVID-19 patients, while surgical sites remain in the process of trying to get back up and running amid shelter-in-place guidance. Therefore, we believe site initiations and patient enrollment are to continue to be site specific for the foreseeable future, based on available site resources and overall quarantine guidelines.” That being said, Fein remains optimistic about the PB2452 platform, as it “directly addresses the unmet therapeutic need in antiplatelet patients facing major bleeding and urgent surgery circumstances that could otherwise result in death or treatment delay.” He added, “We point out there are no ticagrelor or antiplatelet reversal agents, and ticagrelor reversibly binds the P2Y12 receptor, making it the only potentially reversible oral antiplatelet therapy.”Although enrollment was halted for the Phase 2 PB1046 program, the fact that PB2452 Phase 2a data could potentially be presented during the upcoming European Society of Cardiology (ESC) 2020 virtual conference in August 2020 seals the deal for Fein. To this end, Fein maintained a Buy rating on PHAS with an $18 price target, suggesting 298% upside potential from current levels. (To watch Fein’s track record, click here) Looking at the consensus breakdown, other analysts are on the same page. With 5 Buys and no Holds or Sells, the word on the Street is that PHAS is a Strong Buy. The $13 average price target puts the upside potential at 187%. (See PhaseBio stock analysis on TipRanks)Diffusion Pharmaceuticals (DFFN)As for the final stock on our list, Diffusion Pharmaceuticals develops new treatments for life-threatening medical conditions by improving the body’s ability to deliver oxygen to the areas where it is needed most. Currently going for $0.95 apiece, one analyst thinks that now is the time to snap up shares.Covering DFFN for H.C. Wainwright, analyst Swayampakula Ramakanth is looking forward to the initiation of its COVID-19 study. At the end of May, the company received a response from the FDA regarding its Pre-Investigational New Drug (PIND) meeting request on the proposed clinical development program to assess trans sodium crocetinate (TSC) in COVID-19 patients with severe respiratory symptoms and low oxygen levels.The FDA stated the study should be designed as a double-blinded, controlled, randomized trial by including Gilead’s COVID-19 treatment, remdesivir, as a component of standard of care for hospitalized patients. Additionally, the agency also accepted the proposed safety and oxygenation marker endpoints.If that wasn’t enough, Ramakanth highlights the fact that a European COVID-19 study of TSC will be conducted in collaboration with the Romanian National Institute of Infectious Diseases (NIID), which is the largest provider of treatment for COVID-19 patients in Romania. “Diffusion expects to enroll the first patient for the European study in June, upon regulatory approval, and report initial data in 3Q20, which we believe could be a catalyst,” the analyst said.It’s true that the ongoing public health crisis could slow down the enrollment for its Phase 2 PHAST-TSC (Pre-Hospital Administration of Stroke Therapy-TSC) stroke study, designed to evaluate the therapy as an acute stroke treatment. That said, Ramakanth remains unphased by a possible delay.“In our view, given that the pandemic is starting to abate and TSC is being studied as acute treatment, Diffusion could be able to get the PHAST-TSC study completed as planned. While reporting the company’s 4Q19 earnings, management stated their expectation to complete the study enrollment in 2021 and report topline data in 2022,” the analyst explained.Based on all of the above, Ramakanth rates DFFN a Buy along with a $3.50 price target. This target suggests shares could soar 286% in the next twelve months. (To watch Ramakanth’s track record, click here)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
- 07/06/2020
|
UK emergency remdesivir supplies adequate to treat COVID-19, official says
- Britain has adequate supplies of Gilead's remdesivir for emergency use to treat hospitalised COVID-19 patients, England's deputy chief medical officer said on Wednesday, though he warned of potential difficulties securing future supplies.
- 07/01/2020
|
UK emergency remdesivir supplies adequate to treat COVID-19, official says
- Britain has adequate supplies of Gilead's remdesivir for emergency use to treat hospitalised COVID-19 patients, England's deputy chief medical officer said on Wednesday, though he warned of potential difficulties securing future supplies.
- 07/01/2020
|
UK emergency remdesivir supplies adequate to treat COVID-19, official says
- Gilead said this week it had allocated nearly all of its supply of the antiviral to the United States over the next three months, stirring concerns about availability elsewhere, particularly in regions where infection rates are still high. "I judge us to have adequate stocks," Jonathan Van-Tam, deputy chief medical officer and lead for the Department for Health and Social Care, told a parliamentary hearing.
- 07/01/2020
|
Analysts Are Bullish on These Healthcare Stocks: Avid Bioservices (CDMO), Vericel (VCEL) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Avid Bioservices
- 07/01/2020
|
UK emergency remdesivir supplies adequate to treat COVID-19, official says
- UK emergency remdesivir supplies adequate to treat COVID-19, official says
- 07/01/2020
|
Brokerages Anticipate Tristate Capital Holdings Inc (NASDAQ:TSC) Will Announce Quarterly Sales of $50.02 Million
- Equities research analysts expect Tristate Capital Holdings Inc (NASDAQ:TSC) to post sales of $50.02 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Tristate Capital’s earnings, with the lowest sales estimate coming in at $44.80 million and the highest estimate coming in at $53.27 million. Tristate Capital posted sales of […]
- 06/30/2020
|
CEL-SCI Corporation Receives $10 Million Through Warrant Exercises
- CEL-SCI Corporation receives $10 million through warrant exercises.
- 06/30/2020
|
Where Will GW Pharmaceuticals Be in 1 Year? | The Motley Fool
- Here's why this shares of this cannabinoid drug company will keep soaring within the next year.
- 06/29/2020
|
Better Buy: GW Pharmaceuticals vs. Cara Therapeutics | The Motley Fool
- Both of these biotechs could have big catalysts on the way.
- 06/28/2020
|
H.C. Wainwright Maintains a Buy Rating on Tyme Technologies (TYME) - Markets
- In a report issued on June 24, Swayampakula Ramakanth from H.C. Wainwright maintained a Buy rating on Tyme Technologies (TYME
- 06/28/2020
|
BSV Technical Standards Committee Formation Meeting highlights - CoinGeek
- The group’s goal is to create a roadmap that increases the likelihood of interoperability across the Bitcoin SV ecosystem.
- 06/25/2020
|
Two Sigma Investments LP Raises Stake in Tristate Capital Holdings Inc (NASDAQ:TSC)
- Two Sigma Investments LP boosted its position in Tristate Capital Holdings Inc (NASDAQ:TSC) by 629.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 79,534 shares of the financial services provider’s stock after buying an additional 68,634 shares […]
- 06/25/2020
|
Investment Analysts’ Recent Ratings Changes for Tristate Capital (TSC)
- A number of research firms have changed their ratings and price targets for Tristate Capital (NASDAQ: TSC): 6/24/2020 – Tristate Capital was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Tristate Capital Holdings, Inc. is a bank holding company for TriState Capital Bank. The company […]
- 06/25/2020
|
TriState Capital Schedules July 23 Conference Call to Review Second Quarter 2020 Financial Results
- TriState Capital Holdings, Inc. (Nasdaq: TSC) scheduled a conference call for Thursday, July 23, 2020 to review its second quarter 2020 financial resu
- 06/25/2020
|
Codexis (CDXS) Gets a Buy Rating from H.C. Wainwright - Markets
- H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on Codexis (CDXS – Research Report) today and set a price
- 06/24/2020
|
CEL-SCI to Present at H.C. Wainwright Virtual Fireside Chat Series
- CEL-SCI to Present at H.C. Wainwright Virtual Fireside Chat Series
- 06/24/2020
|
TEKLYNX International und Printronix Auto ID bringen die
branchenweit erste Etikettierlösung mit umfangreichen Fähigkeiten
zur Etikettenprüfung und durchgehender Barcode-Verifizierung auf den
Markt
- Neue Integration von Software zur Rückverfolgbarkeit von Etiketten und ODV-2D-Drucker verfolgt die Etikettierung vom Design bis zum Druck, um Unternehmen zu einer besseren Etikettierung zu verhelfen
- 06/23/2020
|
3 Financial Stocks Worth Considering in a Rebounding Economy
- Ally Financial, B. Riley Financial and TriState Capital should see their prospects improve as economic activity picks up.
- 06/22/2020
|
Companies Urged to Fortify Supply Chains from Climate Change Disruption
- Report from HSBC and The Sustainability Consortium urges businesses to prepare supply chains for climate change and helps them understand risks
- 06/22/2020
|
6 sites in MMR are now wetlands
|
Tristate Capital (NASDAQ:TSC) Stock Rating Upgraded by Raymond James
- Raymond James upgraded shares of Tristate Capital (NASDAQ:TSC) from an outperform rating to a strong-buy rating in a report published on Wednesday, The Fly reports. They currently have $20.00 target price on the financial services provider’s stock, up from their prior target price of $15.00. A number of other equities research analysts have also weighed […]
- 06/21/2020
|
Citigroup Inc. Sells 22,836 Shares of Tristate Capital Holdings Inc (NASDAQ:TSC)
- Citigroup Inc. lowered its stake in Tristate Capital Holdings Inc (NASDAQ:TSC) by 66.4% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 11,548 shares of the financial services provider’s stock after selling 22,836 shares during the quarter. Citigroup Inc.’s holdings in Tristate Capital were worth $112,000 at the […]
- 06/20/2020
|
European Cinema Giant Vue Rejigs Leadership in U.K., Italy Ahead of Theaters Reopening
- As it looks to reopen its theaters after the coronavirus lockdown, European cinema giant Vue International has restructured its leadership across the U.K. and Italy. Toby Bradon, general manager of Vue's Italian business The Space Cinema, will switch markets, taking on the role of territory general manager for Vue U.K., Ireland and Denmark. He will […]
- 06/19/2020
|
DIFFUSION PHARMACEUTICALS INC. : Submission of Matters to a Vote of Security Holders (form 8-K) | MarketScreener
|
H.C. Wainwright Reiterates Their Buy Rating on Zomedica Pharmaceuticals (ZOM) - Markets
- In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Zomedica Pharmaceuticals (ZOM – Research
- 06/17/2020
|
TSC Talks Hosts Facebook Live on “The Tower of Babel: Parenting & Healthcare in America Today”
- 18 at 7 PM EST to provide an open forum for discussing the growing demands on the American family when a family member has a chronic medical problem. Healthcare
- 06/16/2020
|
KNUT asks TSC to review staffing norm in schools before re-opening
- NAIROBI, Kenya Jun 16 – Kenya National Union of Teachers (KNUT) has asked the Teachers Service Commission (TSC) to review the staffing norms in order to address the changing dynamics in the education sector occasioned by the coronavirus pandemic in the country. The union’s Secretary General Wilson Sossion challenged TSC boss Nancy Macharia to ensure […]
- 06/16/2020
|
Diffusion Pharmaceuticals (NASDAQ:DFFN) Receives Media Impact Rating of -3.53
- News articles about Diffusion Pharmaceuticals (NASDAQ:DFFN) have trended very negative on Tuesday, InfoTrie Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than 6,000 news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being […]
- 06/16/2020
|
Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (NASDAQ: KALV), Atara Biotherapeutics (NASDAQ: ATRA) and EKSO BIONICS (NASDAQ: EKSO) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on KalVista Pharmaceuticals
- 06/15/2020
|
Over 1m ‘locked out’ of coronavirus income support schemes, MPs warn
- The government must extend its coronavirus income support measures to cover a million people who have “fallen through the gaps” in the schemes, MPs said.
- 06/15/2020
|
El SEM catalán compra decenas de coches y provoca un cisma en la cúpula sanitaria
- Se han comprado coches que no se tenían que comprar y se han comprado hospitales de campaña hinchables que a estas alturas ya no se van a usar. Esto es un desbarajuste total
- 06/13/2020
|
New Product Released on Crowdfunding Site Indiegogo Captures the Entourage Effect without THC
- For the last decade, Mike Robinson has been a pioneer in providing Compassion Cannabis care to individuals who either cannot find or cannot afford care for
- 06/12/2020
|
ViiV Healthcare announces US FDA approval of the first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children living with HIV
- US FDA approves first-ever dispersible tablet formulation of dolutegravir, Tivicay PD, a once-daily treatment for children
- 06/12/2020
|
BioCryst Berotralstat PDUFA, And Other News: The Good, Bad And Ugly Of Biopharma (NASDAQ:BCRX)
- BioCryst's Berotralstat PDUFA has been set for December 3, 2020. Sarepta progresses with muscular dystrophy study. Aimmune's Palforzia produces positive data.
- 06/11/2020
|
Diffusion Pharmaceuticals Files Clinical Trial Application for European Phase 1a/1b Study of TSC in COVID-19 Patients
- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “Company”) announces the submission of a Clinical Trial Application (CTA) to the Romanian National
- 06/11/2020
|
‘Why Gombe set up teacher training centre’
- Growing concerns over academic underachievement of students and the need to send high quality teachers into classrooms in Gombe State have led to the establishment of a Teacher Training Centre (TTC…
- 06/11/2020
|
Alligator Energy adds to South Australian uranium portfolio as spot price holds gains
- Alligator Energy (ASX: AGE) will acquire a uranium resource in South Australia holding 46.6 million pounds of uranium oxide that has languished since its 2007 discovery.
- 06/11/2020
|
1 Cannabis Stock Beating the Market This Year | The Motley Fool
- GW Pharma has been performing well recently, but is this cannabis stock a buy?
- 06/10/2020
|
Analysts Are Bullish on These Healthcare Stocks: Kindred Biosciences (KIN), Gilead Sciences (GILD) - Markets
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kindred Biosciences
- 06/10/2020
|
Tristate Capital (NASDAQ:TSC) Rating Increased to Buy at BidaskClub
- Tristate Capital (NASDAQ:TSC) was upgraded by investment analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued on Wednesday, BidAskClub reports. TSC has been the topic of several other research reports. Zacks Investment Research raised shares of Tristate Capital from a “sell” rating to a “hold” rating in a […]
- 06/10/2020
|
Bank of New York Mellon Corp Boosts Position in Tristate Capital Holdings Inc (NASDAQ:TSC)
- Bank of New York Mellon Corp grew its position in Tristate Capital Holdings Inc (NASDAQ:TSC) by 12.8% in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 411,337 shares of the financial services provider’s stock after buying an additional 46,698 […]
- 06/10/2020
|
Immutep (ASX:IMM) TACTI-002 and INSIGHT Clinical Results & Update
- 09 Jun 2020 - Immutep Limited (ASX:IMM) Executive Director and CEO Marc Voigt, Chief Scientific and Medical Officer Dr Frédéric Triebel, and Director Clinical Development and Regulatory Affairs Christian Mueller present on Immutep's latest clinical results.
- 06/09/2020
|
Aurinia Presents Additional AURORA Pivotal Trial Safety Data at the ERA-EDTA Virtual Congress 2020
- Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancin
- 06/09/2020
|
Material Processing Institute at forefront of £10m innovation project
- The Middlesbrough business is playing a leading role in the project, which involves four other firms
- 06/08/2020
|
Here's Why Timber Pharmaceuticals' Three Shots On Goal And Strong Balance Sheet May Equate To Near-Term Success | MarketScreener
|
200 jobs at risk at Scunthorpe soup and sauce manufacturer
- TSC Foods is heavily reliant on the foodservice sector and has reported a 75 per cent drop in business
- 06/05/2020
|
200 jobs to go at food factory as a result of coronavirus outbreak
- Here's the latest
- 06/05/2020
|
Huge jobs blow as TSC Foods factory to axe up to 200 staff
- TSC Foods in Scunthorpe says it has seen a 75 per cent decline in business as a result of the crisis
- 06/05/2020
|
Aurinia Presents AURORA Pivotal Trial Subgroup Analysis at the EULAR 2020 E-Congress
- Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancin
- 06/05/2020
|
Houston drill pipe manufacturer may layoff entire workforce amid oil bust
- Texas Steel Conversion said it might cut all of its employees — nearly 500 people — due to the oil bust sparked by the coronavirus.
- 06/04/2020
|
Diffusion Pharmaceuticals Regains Compliance with NASDAQ Minimum Bid Price Requirement
- The Company had previously been notified by Nasdaq on December 11, 2019 that it was not in compliance with the minimum bid price rule because its common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days. In order to regain compliance with Listing Rule 5550(a)(2), the Company was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive trading days, which was achieved on May 28, 2020. The Company’s last closing bid price on May 28 was $1.27.
- 06/01/2020
|
2020 Settings of React TypeScript Project with webpack and Babel
- With create-react-app, you can properly and super easily setup a React TypeScript project. But what if you predict your application…
- 05/31/2020
|
GW Pharma: Analysts Aren't Thinking Clearly (NASDAQ:GWPH)
- Analysts may have it wrong on GWPH revenues. A warehousing effect ex-US may have flattered revenues, but that doesn't mean Q2'20 will be a weak quarter. US Epid
- 05/28/2020
|
Diffusion Pharmaceuticals Receives Accelerated FDA Response to Proposed TSC COVID-19 Clinical Trial Program
- The PIND was filed on April 27, seeking FDA guidance on the Company’s proposed clinical development program for the use of trans sodium crocetinate (TSC) in COVID-19 patients displaying severe respiratory symptoms and low oxygen levels. The FDA’s accelerated response to the PIND meeting request recommended that the first U.S. TSC COVID-19 study employ a double-blinded, controlled, randomized clinical trial design to address the wide variability in standard of care due to the rapidly evolving COVID-19 experience.
- 05/26/2020
|
CEL-SCI: What's Next (NYSEMKT:CVM)
- Phase III trial recently ended. Top line data results very soon. SEER data points to success. Price target $200 upon approval.
- 05/26/2020
|
10 at 10: These 10 ASX stocks are gliding through the skies this morning - Stockhead
- Stockhead’s Top 10 at 10 highlights the best (and worst) performing ASX small caps in morning trade. It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms. The market opens at 10am (eastern time) and the data is taken at 10:15am, once every stock has commenced trading. …
- 05/26/2020
|
Aurinia Completes Submission of New Drug Application to the U.S. Food & Drug Administration for Voclosporin for the Treatment of Lupus Nephritis
- Aurinia Pharmaceuticals Inc. (Nasdaq:AUPH / TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancin
- 05/26/2020
|
Cel-Sci: A Zombie Biotech Company (NYSEMKT:CVM)
- Cel-Sci has been dragging a drug trial on for years which should have been stopped in 2014 on the recommendation of their Independent Data Monitoring Committee.
- 05/23/2020
|
TriState Capital Announces Change to Virtual-Only 2020 Annual Meeting of Shareholders
- TriState Capital Holdings, Inc. (Nasdaq: TSC) announced today that it will hold its 2020 Annual Meeting of Shareholders (the “ Annual Meeting”) solely
- 05/21/2020
|
Diffusion Pharmaceuticals Inc. Announces Closing of $12.0 Million Registered Direct Offering Priced At-the-Market
- The gross proceeds to Diffusion, before deducting placement agent fees and other offering expenses, were approximately $12.0 million. Diffusion currently intends to use the net proceeds from the offering to fund research and development of its lead product candidate, TSC, including clinical trial activities, and for general corporate purposes.
- 05/20/2020
|
Diffusion Pharmaceuticals Expands Clinical Trial Program of TSC for the Treatment of COVID-19 Patients to Include the Romanian National Institute of Infectious Diseases
- CHARLOTTESVILLE, Va., May 20, 2020 -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new.
- 05/20/2020
|
Johns Hopkins doctor on Trump's preventative hydroxychloroquine use: 'hopefully other people will not follow this example'
- Johns Hopkins Center for Health Security Senior Scholar Dr. Amesh Adalja joins Yahoo Finance’s Seana Smith to discuss President Trump’s remarks that he is taking hydroxychloroquine as a preventative measure against COVID-19.
- 05/19/2020
|
DFFN: TSC to be Tested as Treatment for ARDS Caused by COVID-19…
- By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Waiting for Response on Pre-IND Submission for TSC in COVID-19 ARDS On April 27, 2020, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) announced the company’s Pre-IND submission to the U.S. FDA for the use of the company’s lead development compound, trans sodium crocetinate (TSC), for the treatment of acute
- 05/19/2020
|
Diffusion Pharmaceuticals Inc. Announces $12 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
- The gross proceeds to Diffusion, before deducting placement agent fees and other offering expenses, are expected to be approximately $12.0 million. The closing is expected to occur on or about May 20, 2020, subject to the satisfaction of customary closing conditions. Diffusion currently intends to use the net proceeds from the offering to fund research and development of its lead product candidate, TSC, including clinical trial activities, and for general corporate purposes.
- 05/18/2020
|
Ethereum Privacy Tool Tornado Cash on the Verge of Being "Unstoppable"
- Tornado is a mixer built on Ethereum that relies on special cryptographic proofs called zk-SNARKs to make ether (ETH) transactions totally anonymous.
- 05/14/2020
|
GW Pharmaceuticals (GWPH): Investments in manufacturing and international expansion serve as strong growth drivers | AlphaStreet
- GW Pharmaceuticals plc (NASDAQ: GWPH) has seen its stock gain over 17% in the past one month.
- 05/12/2020
|
GW Pharmaceuticals PLC (NASDAQ: GWPH) Q1 2020 Earnings Call Transcript | AlphaStreet
- Final earnings conference call transcript of GW Pharmaceuticals PLC - GWPH stock
- 05/12/2020
|
GW Pharmaceuticals PLC (GWPH) CEO Justin Gover on Q1 2020 Results - Earnings Call Transcript
- GW Pharmaceuticals PLC (NASDAQ:GWPH) Q1 2020 Earnings Conference Call May 11, 2020, 16:30 ET Company Participants Stephen Schultz - VP, IR Justin Gover - CEO &a
- 05/12/2020
|
New Research Highlights Farmer Perspectives on Farm-Level Data Collection and Sharing
- LENEXA, Kan., May 11, 2020 /PRNewswire via COMTEX/ --
LENEXA, Kan., May 11, 2020 /PRNewswire/ -- Several challenges prevent farmers from collecting and...
- 05/11/2020
|
Diffusion Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Business Update
- CHARLOTTESVILLE, Va., May 11, 2020 -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new.
- 05/11/2020
|
Deno 1.0 – "Deno is a web browser for command-line scripts" - JAXenter
- Deno 1.0 is scheduled to arrive on May 13. For this occasion, we spoke to Deno inventor Ryan Dahl about how Deno differs from Node.
- 05/11/2020
|
CEL-SCI Corporation Reports Second Quarter Fiscal 2020 Financial Results
- CEL-SCI Corporation reports second quarter fiscal 2020 financial results.
- 05/11/2020
|
Hypoxic Training Equipment Market Worth $230 Million by 2026: Next Generation Health and Fitness - ResearchAndMarkets.com
|
GW Pharmaceuticals Q1 Results Will Provide Important Markers For The Coming Year
- Company operations should have been only mildly affected by COVID-19 pandemic. There have recently been further positive developments for the company. Expansion
- 05/05/2020
|
Diffusion Pharmaceuticals Announces FDA Accelerated Review of TSC Clinical Development Plan to Treat COVID-19 Patients with ARDS
- Inclusion in FDA’s Coronavirus Treatment Acceleration Program significantly shortens regulatory review cycles Simultaneous patient enrollment planned in both the U.S. and.
- 05/05/2020
|
CEL-SCI’s Pivotal Phase 3 Study Has Reached the Required Number of Events to Evaluate Data for Multikine in Treatment of Head and Neck Cancer
- CEL-SCI’s Pivotal Phase 3 Study has reached the required number of events to evaluate data for Multikine in treatment of Head and Neck Cancer.
- 05/04/2020
|
Analysts Offer Insights on Healthcare Companies: Amarin (AMRN), Viking Therapeutics (VKTX) and Corvus Pharmaceuticals (CRVS)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amarin (AMRN), Viking Therapeutics (VKTX) and Corvus
- 05/01/2020
|
Analysts Offer Insights on Healthcare Companies: Amarin (NASDAQ: AMRN), Viking Therapeutics (NASDAQ: VKTX) and Corvus Pharmaceuticals (NASDAQ: CRVS)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amarin (
AMRN
–
Research Report
), Viking Therapeutics (
VKTX
–
Research Report
) and Corvus Pharmaceuticals (
CRVS
–
Research Report
) with bullish sentim
- 05/01/2020
|
Diffusion Pharmaceuticals Announces Pre-IND Submission to the FDA of Design for TSC Trials to Treat Acute Respiratory Distress Syndrome in COVID-19
- Under federal regulations, the FDA has up to 60 days to hold an advisory meeting with the Company, but for COVID-19-related submissions, the FDA has announced its intention to significantly shorten this period under its Coronavirus Treatment Acceleration Program. Clinical trial start-up preparations are continuing as the Company awaits the FDA’s response.
- 04/27/2020
|
Amid Lockdown, Thousands Of Flamingos Turn Creek Near Mumbai Pink
- A sea of pink dazzled residents of Navi Mumbai as thousands of flamingos settled along the creek on Thursday morning. The migratory birds, which visit Mumbai every year, have arrived in huge numbers, in the middle of a lockdown to check the spread of coronavirus.
- 04/23/2020
|
Going viral: All the biggest COVID-19 news from the last week - Stockhead
- Welcome to our wrap for investors of the key coronavirus news this week. By the numbers Australian deaths: 66, up 47 per cent on last week Australian cases: 6,521, up 8 per cent on last week Global deaths: 145,568, up 77 per cent on last week Global cases: 2,159,450, up 50 per cent on last …
- 04/17/2020
|
Miner ID and Merchant API bring Bitcoin SV closer towards global P2P cash system - CoinGeek
- The tools, announced on April 3, are part of the Bitcoin SV community's initiative to grow enterprise adoptions and instant transactions.
- 04/07/2020
|
DFFN: Evaluating TSC as Potential Treatment for ARDS…
- By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Evaluating TSC as Treatment for ARDS On April 1, 2020, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) announced that the company will be evaluating its lead development compound, trans sodium crocetinate (TSC), for the treatment of acute respiratory distress syndrome (ARDS) as a result of infection with the novel
- 04/03/2020
|
Analysts Offer Insights on Healthcare Companies: Dynavax (DVAX), Crinetics Pharmaceuticals (CRNX) and Collplant Holdings (CLGN)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX), Crinetics Pharmaceuticals (CRNX) and
- 04/03/2020
|
Analysts Offer Insights on Healthcare Companies: Dynavax (NASDAQ: DVAX), Crinetics Pharmaceuticals (NASDAQ: CRNX) and Collplant Holdings (NASDAQ: CLGN)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX
- 04/03/2020
|
Diffusion Pharmaceuticals Evaluating TSC Against Acute Respiratory Distress Syndrome (ARDS) in COVID-19 Patients
- CHARLOTTESVILLE, Va., April 01, 2020 -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or “the Company”), a cutting-edge biotechnology company developing new.
- 04/01/2020
|
Diffusion Pharma To Evaluate Drug In COVID-19-Related Respiratory Distress, Sending Stock Higher
- Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) shares were more than doubling Wednesday following an announcement by the company regarding testing of its lead asset for COVID-19-...
- 04/01/2020
|
Hyperledger Besu graduates to active project status » CryptoNinjas
- The Hyperledger Besu team, today announced Hyperledger’s Technical Steering Committee (TSC) voted to graduate the project from incubation to active
- 03/30/2020
|
Analysts Offer Insights on Healthcare Companies: Ocugen (OCGN) and OrthoPediatrics (KIDS)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ocugen (OCGN) and OrthoPediatrics (KIDS) with bullish
- 03/30/2020
|
Analysts Offer Insights on Healthcare Companies: Ocugen (NASDAQ: OCGN) and OrthoPediatrics (NASDAQ: KIDS)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ocugen (OCGN
- 03/30/2020
|
Analysts Offer Insights on Healthcare Companies: IntelGenx Technologies (OtherIGXT), Aerpio Pharmaceuticals (ARPO) and Medtronic (MDT)
- Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on IntelGenx Technologies (IGXT), Aerpio Pharmaceuticals
- 03/30/2020
|
Analysts Offer Insights on Healthcare Companies: IntelGenx Technologies (Other OTC: IGXT), Aerpio Pharmaceuticals (NASDAQ: ARPO) and Medtronic (NYSE: MDT)
- Companies in the
Healthcare sector have received a lot of coverage today as analysts
weigh in on IntelGenx Technologies (
IGXT
–
Research Report
), Aerpio Pharmaceuticals (
ARPO
–
Research Report
) and Medtronic (
MDT
–
Research Report
).
IntelGenx T
- 03/30/2020
|
Analysts Are Bullish on These Healthcare Stocks: Celldex (CLDX), Evolus (EOLS)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Celldex (CLDX), Evolus (EOLS) and Vascular Biogenics (VBLT)
- 03/27/2020
|
Analysts Are Bullish on These Healthcare Stocks: Celldex (CLDX), Evolus (EOLS)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Celldex (
CLDX
–
Research Report
), Evolus (
EOLS
–
Research Report
) and Vascular Biogenics (
VBLT
–
Research Report
) with bullish sentiments.
Celldex (C
- 03/27/2020
|
The Daily Biotech Pulse: T2 Biosystems Licenses COVID-19 Test, Immuron CEO Steps Down
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 24) * BELLUS Health Inc (NASDAQ: BLU) * Global Cord Blood Corp (NYSE: CO) * Thermogenesis Holdings Inc (NASDAQ: THMO)(reacted to its fourth-quarter
- 03/25/2020
|
Codexis (CDXS) Gets a Buy Rating from H.C. Wainwright
- In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Codexis (CDXS), with a price target of $22.50. The
- 03/25/2020
|
Coronavirus activity roundup - healthcare
- PRA Health Sciences (NASDAQ:PRAH) has expanded its Mobile Health Platform for remote clinical monitoring, adding new capabilities that address sponsor needs for COVID-19 virtual study support.Diffusio
- 03/24/2020
|
Diffusion Pharmaceuticals Anticipates Enrollment in its Ambulance-based Stroke Trial Will be Slowed Due to the Impact of the Coronavirus
- The LA County Fire Department has informed us that, due to the necessity to respond to the pandemic, it is suspending future training of first responders who had been scheduled to participate in the trial protocol. Such disruptions are expected to delay the Company’s previously announced timeline for study completion.
- 03/24/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Geron (GERN), Electrocore (ECOR) and CytomX Therapeutics
- 03/24/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Geron (GERN
- 03/24/2020
|
Merus (NASDAQ:MRUS) & Diffusion Pharmaceuticals (NASDAQ:DFFN) Financial Analysis
- Merus (NASDAQ:MRUS) and Diffusion Pharmaceuticals (NASDAQ:DFFN) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability. Analyst Recommendations This is a breakdown of current ratings for Merus and Diffusion Pharmaceuticals, as provided […]
- 03/23/2020
|
An Eye on Valuation Metrics Of TriState Capital Holdings, Inc.(TSC), ONE Gas, Inc.(OGS) | Post Analyst
- TriState Capital Holdings, Inc. (TSC) is now among the bigger bargains in its industry. Within the last year the price ranged from $7.6 – 26.44 and there is a wide opportunity to get in. Its next earnings report will be released on Apr 20, 2020. ONE Gas, Inc.(OGS) move, based on 4 analysts offering 12 …
- 03/20/2020
|
Is Diffusion Pharmaceuticals (NASDAQ:DFFN) In A Good Position To Deliver On Growth Plans?
- We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
- 03/19/2020
|
CORRECTION -- Diffusion Pharmaceuticals Reports 2019 Financial Results and Provides Business Update
- $16.2 Million in Gross Proceeds RaisedNow Enrolling in Acute Stroke TrialGBM Data PresentedNew Board Appointment CHARLOTTESVILLE, Va., March 18, 2020 -- In the news release.
- 03/18/2020
|
4 Stocks Moving In Tuesday's After-Hours Session
- Gainers
Network-1 Technologies (NASDAQ: NTIP) shares are trading higher after the company received a new patent from the U.S. Patent Office.
Arbor Realty Trust (NYSE:...
- 03/17/2020
|
Diffusion Pharmaceuticals Reports 2019 Financial Results and Provides Business Update
- $16.2 Million in Gross Proceeds RaisedNow Enrolling in Acute Stroke TrialGBM Data PresentedNew Board Appointment CHARLOTTESVILLE, Va., March 17, 2020 -- Diffusion.
- 03/17/2020
|
Kindred Biosciences (KIN) Receives a Buy from H.C. Wainwright
- In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Kindred Biosciences (KIN), with a price target of
- 03/17/2020
|
Kindred Biosciences (KIN) Receives a Buy from H.C. Wainwright
- In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Kindred Biosciences (KIN – Research
- 03/17/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aquestive Therapeutics (AQST) and Verastem (VSTM) with
- 03/16/2020
|
Analysts Are Bullish on These Healthcare Stocks: Lineage Cell Therapeutics (LCTX), Menlo Therapeutics (MNLO)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Lineage Cell Therapeutics (LCTX), Menlo Therapeutics (MNLO)
- 03/13/2020
|
Diffusion Pharmaceuticals Announces Retirement of Chief Science Officer John L. Gainer
- Dr. Gainer will continue to serve as both an advisor to the Company and as a member of the board of directors. In recognition of the advancement of the TSC technology into the clinic, the Company has begun a search for a Chief Medical Officer as a replacement for the former Chief Science Officer position.
- 03/12/2020
|
Analysts Offer Insights on Healthcare Companies: Dynavax (DVAX), Proteostasis Therapeutics (PTI) and Inmune Bio (INMB)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX), Proteostasis Therapeutics (PTI) and Inmune
- 03/12/2020
|
Analysts Offer Insights on Healthcare Companies: Dynavax (NASDAQ: DVAX), Proteostasis Therapeutics (NASDAQ: PTI) and Inmune Bio (NASDAQ: INMB)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX
- 03/12/2020
|
Analysts Offer Insights on Healthcare Companies: ChemoCentryx (CCXI), Crinetics Pharmaceuticals (CRNX) and Trillium Therapeutics (TRIL)
- Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on ChemoCentryx (CCXI), Crinetics Pharmaceuticals (CRNX) and
- 03/11/2020
|
Analysts Offer Insights on Healthcare Companies: ChemoCentryx (NASDAQ: CCXI), Crinetics Pharmaceuticals (NASDAQ: CRNX) and Trillium Therapeutics (NASDAQ: TRIL)
- Companies in the
Healthcare sector have received a lot of coverage today as analysts
weigh in on ChemoCentryx (
CCXI
–
Research Report
), Crinetics Pharmaceuticals (
CRNX
–
Research Report
) and Trillium Therapeutics (
TRIL
–
Research Report
).
Chemo
- 03/11/2020
|
Nygard Group seeks creditor protection, plans restructuring after sexual assault allegations against founder
- The company said it has faced pressure from one of its lenders after new allegations against Peter Nygard
- 03/10/2020
|
Schools close in north-east Kenya after al-Shabaab targets teachers
- Authorities face criticism for withdrawing teaching staff from an already marginalised region where education is badly needed
- 03/10/2020
|
Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (ATEC) and BioCryst (BCRX)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alphatec Holdings (ATEC) and BioCryst (BCRX) with bullish
- 03/06/2020
|
Analysts Offer Insights on Healthcare Companies: Alphatec Holdings (NASDAQ: ATEC) and BioCryst (NASDAQ: BCRX)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alphatec Holdings
- 03/06/2020
|
H.C. Wainwright Reiterates Their Buy Rating on Ziopharm Oncology (ZIOP)
- H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Ziopharm Oncology (ZIOP) today and set a price target of $6.50. The company's
- 03/03/2020
|
H.C. Wainwright Reiterates Their Buy Rating on Ziopharm Oncology (ZIOP)
- H.C. Wainwright analyst
Swayampakula Ramakanth
reiterated a
Buy
rating on Ziopharm Oncology (
ZIOP
–
Research Report
) today and set a price target of
$6.50
. The company’s shares closed last Monday at $2.90, close to its 52-week low of $2.68.
Accord
- 03/03/2020
|
Retailers dropping Nygard brands amid latest sexual assault allegations
- An exodus of clientele presents an existential threat to the Winnipeg-based company, with or without Peter Nygard at the helm
- 02/28/2020
|
H.C. Wainwright Reiterates a Buy Rating on Codexis (CDXS)
- In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Codexis (CDXS), with a price target of $22.50. The
- 02/28/2020
|
Analysts Are Bullish on These Healthcare Stocks: Vericel (VCEL), Amarin (AMRN)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vericel (VCEL), Amarin (AMRN) and Jazz Pharmaceuticals
- 02/26/2020
|
Analysts Are Bullish on These Healthcare Stocks: Vericel (VCEL), Amarin (AMRN)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Vericel (
VCEL
–
Research Report
), Amarin (
AMRN
–
Research Report
) and Jazz Pharmaceuticals (
JAZZ
–
Research Report
) with bullish sentiments.
Vericel
- 02/26/2020
|
H.C. Wainwright Sticks to Its Buy Rating for Corcept Therapeutics (CORT)
- H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Corcept Therapeutics (CORT) today and set a price target of $18.00. The
- 02/21/2020
|
H.C. Wainwright Sticks to Its Buy Rating for Corcept Therapeutics (CORT)
- H.C. Wainwright analyst Swayampakula Ramakanth reiterated a Buy rating on Corcept Therapeutics (CORT – Research Report) today and set a
- 02/21/2020
|
Analysts Offer Insights on Healthcare Companies: IMV (NASDAQ: IMV), Pluristem (NASDAQ: PSTI) and uniQure (NASDAQ: QURE)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on IMV (IMV
- 02/10/2020
|
Diffusion Pharmaceuticals Receives European Patent Related Compositions of TSC
- This patent relates to pharmaceutical compositions of trans sodium crocetinate (“TSC”) and a cyclodextrin for use in therapy. Specifically claimed are TSC compositions are for use in conjunction with radiation or chemotherapy. Secondary claims relate to various compositions of TSC.
- 02/07/2020
|
GW Pharma submits supplemental NDA for Epidiolex to treat seizures from TSC
- GW Pharmaceuticals PLC undefined said Monday it has submitted a supplemental New Drug Application (NDA) to expand the label for Epidiolex cannabidiol oral...
- 02/03/2020
|
Analysts Are Bullish on These Healthcare Stocks: Clovis Oncology (CLVS), Corcept Therapeutics (CORT)
- There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Clovis Oncology (CLVS), Corcept Therapeutics (CORT) and
- 01/31/2020
|
Analysts Are Bullish on These Healthcare Stocks: Clovis Oncology (CLVS), Corcept Therapeutics (CORT)
- There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Clovis Oncology (
CLVS
–
Research Report
), Corcept Therapeutics (
CORT
–
Research Report
) and Vertex Pharmaceuticals (
VRTX
–
Research Report
) with bull
- 01/31/2020
|
Facebook’s Libra Cryptocurrency Launch ‘Failed’! - KOINPOST
- Facebook’s Libra Cryptocurrency Launch ‘Failed’ to launch in 2020. Libra Association formed a new and independent Technical Steering Committee (TSC).
- 01/21/2020
|
Dream the dream and business glory may become reality...
- Northern Lincolnshire Business Awards 2020 launches
- 01/21/2020
|
3 Top-Notch "Strong Buy" Stocks Under $3
- If you’re on a budget, yet in a risk-tolerant mood, it’s worth taking a look at penny stocks – companies whose shares sell for less than $5 apiece. Here
- 01/20/2020
|
3 Top Healthcare Stocks That Could Gain 35% -- Or More
- Returns, that’s the name of the investing game. At the end of the day, investors are after the names that can help them generate a profit in the stock
- 01/17/2020
|
Diffusion Pharmaceuticals Appoints Life Sciences Veteran Dr. Robert Cobuzzi, Jr. to its Board of Directors
- CHARLOTTESVILLE, Va., Jan. 10, 2020 -- Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN) (“Diffusion,” the “Company,” “we,” “our” or “us”), a cutting-edge biotechnology company.
- 01/10/2020
|
DFFN: Highly Encouraging Data from Run-in Portion of Phase 3 GBM Trial…
- By David Bautz, PhD NASDAQ:DFFN READ THE FULL DFFN RESEARCH REPORT Business Update Encouraging Data for Dose Escalation Run-in of Phase 3 GBM Trial On December 10, 2019, Diffusion Pharmaceuticals, Inc. (NASDAQ:DFFN) announced the presentation of highly encouraging data from the 19 patient run-in portion of the Phase 3 INvestigating Tsc Against Cancerous Tumors (INTACT) clinical trial of TSC in
- 12/30/2019
|
GW Pharmaceuticals (GWPH) Stock Is Dashing Towards a Brighter Future
- GW Pharmaceuticals (GWPH) announced on Monday that it had received approval to sell its epilepsy drug in the world's largest market, as measured by GDP.
- 09/26/2019
|
Bitcoin Association: Call for interest in new BSV Technical Standards Committee - CoinGeek
- Bitcoin Association announced their intention to create the TSC, and are now calling for expressions of interest from the wider Bitcoin SV society to participate in the TSC process.
- 09/16/2019
|
Hyperledger Releases Cryptographic Toolbox for Developers - BlockBoard
- In an announcement yesterday, the Hyperledger’s Technical Steering Committee (TSC) unveiled a new project called Ursa, designed to be a cryptographic modular intended to help project developers within the Hyperledger blockchain community build resourceful applications seamlessly. Ursa is being touted as a shared “flexible cryptographic library”, allowing developers to tap from a resource pool of … The post Hyperledger Releases Cryptographic Toolbox for Developers appeared first on BitcoinNews.com.
- 12/05/2018
|
TCS wins record 2.25 billion Nielsen contract, Accenture gets Vatican deal
- Tata Consultancy Services Ltd. (TCS) has set a record by winning a 2.25 billion dollar outsourcing contract from Nielsen.
- 12/22/2017
|
Power couple: Mixed reality will help businesses cash in on both AR and VR
- Guest Historically, VR and AR have been seen as two separate technologies both having unique case uses. VR has been embraced by gaming enthusiasts as a way to make their gameplay more immersive and relies on a display that is worn over the eyes, tricking the mind into believing it is somewhere else. AR uses a […]
- 11/01/2017
|
“Above the Trend Line” – Your Industry Rumor Central for 6/26/2017 - insideBIGDATA
- Above the Trend Line: your industry rumor central is a recurring feature of insideBIGDATA. In this column, we present a variety of short time-critical news items grouped by category such as people movements, funding news, financial results, industry alignments, rumors and general scuttlebutt floating around the big data, data science and machine learning industries including behind-the-scenes anecdotes and curious buzz.
- 06/26/2017
|
Telecom organizations boosting support for open source
- Organizational support for open source initiatives is easing the integration of platforms into the telecom world. One key challenge for growing the support of open source into the telecommunication…
- 01/23/2017
|
How 'The Syrian Campaign' Faked Its '70% Fleeing Assad' Refugee Poll
- As one might expect, during a war, misunderstandings are often driven by interested parties. In the case of Syrian refugees in Europe a US based organisation called ‘The Syria Campaign’ has helped drive some of these, including a claim that most of the refugees are ‘Fleeing Assad’. ‘The Syria Campaign’ is a Wall Street Public Relations creation and one of several interlocked, US-based groups (Avaaz, Purpose, the White Helmets) which have campaigned for a Libyan-style ‘no fly zone’ in Syria. That is, they work for NATO intervention on the side of the jihadist groups (see Sterling 2015).
- 09/26/2016
|
ALEX BRUMMER: Mike Ashley putting Sports Direct in jeopardy
- There is a negative feedback loop, which started at working conditions, has reached the performance of the company and the share price and contaminated the boardroom.
- 09/07/2016
|
Pam Peirce: What to grow in your food garden
- Bay Area gardeners know our region has a unique climate. Cold summers near the coast limit our success with tomatoes and many other summer crops. Inland, tomatoes and peppers grow better, while the mild winters still allow year-round food gardens. Since I began gardening in San Francisco, in the mid-1970s, I have researched crops that could produce well in cool summers and that were useful for our mild winters. If a particular insect or disease is common here, I sought varieties that would resist it. While I do grow some hybrids, notably those that resist certain diseases, many of my favorites are open-pollinated (plants that can be grown from seeds the plant produces). Catalogs of heirloom seed varieties are often full of mouth-watering photos of tomatoes that, given a nice warm summer, will produce big, delicious fruits. Not to mention eggplants of many colors; peppers in many shapes; melons; flint corn; and dry beans — all beautiful and all beyond the grasp of local coastside gardeners. Look for varieties described as “early” or those from places with higher elevations, which share our cool summer days and nights. Among cool-preferring heirlooms are useful varieties of peas, fava beans, lettuce, collards, kales, broccoli and cabbage, including overwintering broccoli and cabbage varieties. The best varieties for winter are often offered by seed companies located in climates similar to ours, such as western Oregon or British Columbia. Recently, some commercial plant breeders have patented new varieties of seeds or plants they have released, making it illegal for those who buy them to save seed or grow new plants with cuttings. Because of this, some civic-minded plant breeders are releasing new open-pollinated varieties pledged to the new Open Source Seed Initiative (OSSI), a concept inspired by open source software. The OSSI’s motto of Free the Seed refers to freeing seeds from the just-mentioned commercial restrictions forbidding seed saving. Neither the OSSI-pledged variety nor any varieties created using them can be patented or licensed. The initiative wants to create an ever-expanding pool of crop choices that gardeners can use to create new varieties that are even better adapted to particular conditions. Pam Peirce is the author of the regional gardening book “Golden Gate Gardening,” for mid- and Northern California locations both coastal and inland. Open-pollinated seeds are those that can be used to grow a crop, then regrown from seed your plants produce. Offspring will look, act and taste like the parent plant. Chard: ‘Prismatic Rainbow’ (OSSI): Multicolored stems and veins, selected for leaf-miner resistance. Snap pea: ‘Magnolia Blossom’: Climbing habit; red stripe on pod when ready to eat. The exceptions are bush beans and zucchini (and early corn away from the coast), which can be planted until mid-July. Phaseolus coccinius (’Scarlet Runner’): Pole beans with red flowers; eat pods at about 5/8 inches wide or harvest dried beans. Bush beans: ‘Royalty Purple Pod,’ ‘Royal Burgundy,’ ‘Robert’s Royalty’ or ‘Purple Queen’: These seeds are able to germinate in colder soil than many beans, so they get a faster start where cool summers slow growth. Sweet corn: ‘Yukon Supreme’(OSSI): Rated at 51 days from planting; will take longer in cool summers. Capsicum baccatum (species peppers): Big plants from slopes of the Andes. Zucchini: ‘Costata Romanesco’: Ridged and striped fruits are tender babies at 8 inches long. Baker Creek Heirloom Seeds (BC) rareseeds.com, (707) 773-1336 for Petaluma store Southern Exposure Seed Exchange (SESE) southernexposure.com, (540) 894-9480
- 07/02/2016
|
New Zealand’s FMA, the Breder Suasso Conundrum, Mossack Fonseca, and #panamapapers | naked capitalism
- On Breder Suasso, a New Zealand FSP with historic links to disreputable Panamanian law firm Mossack Fonseca
- 04/04/2016
|
Molecular Component for the Cerebellum’s Role in Autism
- Harvard neurologists have identified for the first time a molecular component for the cerebellum’s role in autism, finding that the loss of the TSC1 gene in the Purkinje cells of mice was sufficient to cause autistic-like behaviors. Deleting a single gene in the cerebellum of mice can cause key a
- 07/03/2012
|
